Ethical considerations in the regulation and use of herbal medicines in the European Union

被引:2
|
作者
Gatt, Anthony Raphael [1 ]
Bonanno, Patricia Vella [2 ,3 ]
Zammit, Raymond [1 ]
机构
[1] Univ Malta, Dept Moral Theol, Msida, Malta
[2] Univ Malta, Fac Hlth Sci, Dept Hlth Syst Management & Leadership, Msida, Malta
[3] Univ Strathclyde, Strathclyde Inst Pharm & Biomed Sci, Glasgow, Scotland
来源
关键词
herbal medicines; traditional medicine; pharmaceutical regulation; access to healthcare products; pharmacovigilance; moral awareness; ALTERNATIVE MEDICINE; DIETARY-SUPPLEMENTS; CHINESE MEDICINE; COMPLEMENTARY; PHARMACOVIGILANCE; IDENTIFICATION; ORGANIZATIONS; FRAMEWORK; PRODUCTS; GINSENG;
D O I
10.3389/fmedt.2024.1358956
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
The regulation and use of herbal medicines is a topic of debate due to concerns about their quality, safety, and efficacy. EU Directive 2004/24/EC on Herbal Medicinal Products was a significant step towards establishing a regulatory framework for herbal medicinal products in the EU, and bridging the gap between conventional and herbal medicines. This Directive allows herbal medicinal products to be marketed in the EU through full marketing authorisation, well-established use, and traditional use of herbal medicinal products. The framework relies on the correlation between the therapeutic claims of herbal medicine and the scientific evidence backing them up: the greater the claims made regarding medicinal benefits, the more evidence is required to substantiate its efficacy and safety. This regulatory framework acknowledges and incorporates traditional knowledge when evaluating herbal medicines, showcasing a balanced approach that values cultural traditions while mandating monographs for traditional herbal medicinal products. Excluding herbal medicines completely limits access to affordable treatment, particularly when they serve as the only alternative for some, and protects consumer autonomy. This EU framework could therefore serve as a practical guidance for the use and regulation of herbal medicines, even outside the EU. In conclusion, it is argued that the same moral imagination and courage shown by regulators in the case of herbal medicines could perhaps be used in the regulatory frameworks of other healthcare products.
引用
收藏
页数:14
相关论文
共 50 条
  • [21] Regulation of Obesity by Antiangiogenic Herbal Medicines
    Shin, Soon Shik
    Yoon, Michung
    MOLECULES, 2020, 25 (19):
  • [22] Regulation of Gut Microbiota by Herbal Medicines
    Shinde, Yogita
    Deokar, Gitanjali
    CURRENT DRUG METABOLISM, 2024, 25 (02) : 110 - 127
  • [23] Strengthening the regulation of herbal medicines in Europe
    不详
    LANCET, 2011, 377 (9776): : 1466 - 1466
  • [24] Regulation of plants and herbal medicines in Brazil
    Carvalho, Ana Cecilia B.
    dos Santos, Ligia Aparecida
    Silveira, Damaris
    BOLETIN LATINOAMERICANO Y DEL CARIBE DE PLANTAS MEDICINALES Y AROMATICAS, 2009, 8 (01): : 7 - 11
  • [25] Ethical Perspectives on the European Union
    Durou, Guillaume
    ETUDES INTERNATIONALES, 2012, 43 (02): : 281 - 282
  • [26] European legislation on herbal medicines - A look into the future
    Calapai, Gioacchino
    DRUG SAFETY, 2008, 31 (05) : 428 - 431
  • [27] State of paediatric medicines in the European Union
    Kohl, Stephanie
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2018, 25 (01) : 57 - 57
  • [28] European Union ruling on medicines in children
    Wilkinson, Emma
    LANCET ONCOLOGY, 2006, 7 (07): : 536 - 536
  • [29] Herbal medicines. When to use or not to use?
    Moerike, K.
    Gleiter, C. H.
    INTERNIST, 2014, 55 (11): : 1361 - +
  • [30] The use of real-world evidence in European medicines regulation
    Brown, Jeremy P.
    Wing, Kevin
    Evans, Stephen
    Bhaskaran, Krishnan
    Smeeth, Liam
    Douglas, Ian
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 : 205 - 206